register

News & Trends - Biotechnology

Australian biopharma announces new acquisition

Health Industry Hub | February 9, 2024 |

Biotech News: Melbourne-based Telix Pharmaceuticals is advancing its position in the field of radiopharmaceuticals by entering into an agreement to acquire QSAM Biosciences, a U.S.-based company specialising in the development of therapeutic radiopharmaceuticals for primary and metastatic bone cancer.

The centerpiece of this strategic acquisition is QSAM’s lead investigational drug, Samarium-153-DOTMP (153Sm-DOTMP), a bone-seeking targeted radiopharmaceutical candidate. Utilising a “next generation” chelating agent, the proprietary formulation of Samarium-153 radioisotope in 153Sm-DOTMP shows promise in two major applications – pain management of bone metastases and osteosarcoma therapy, including in paediatric patients.

Telix, known for its focus on urologic oncology, neuro-oncology, and musculoskeletal oncology, sees this alignment with 153Sm-DOTMP as a natural progression in their therapeutic focus areas. The drug has exhibited evidence of safety, efficacy, and future commercial utility in pre-clinical and early clinical trials, presenting potential improvements in the treatment and management of late-stage metastatic disease.

Dr Christian Behrenbruch, Managing Director and Group CEO of Telix, emphasised the transformative potential of the acquisition, stating, “The acquisition of QSAM provides Telix with an additional near-term therapeutic pipeline asset, further differentiating our innovation position in radiopharmaceuticals and building depth in Telix’s key disease focus areas of urological and musculoskeletal oncology.”

153Sm-DOTMP stands out with a significantly improved safety profile, reduced off-target irradiation through more targeted delivery, and a streamlined production system, offering a cost-effective and quality of life-enhancing alternative to standard-of-care treatments. Telix envisions its potential commercialisation as a milestone that builds on an established reimbursement pathway for this class of drugs.

Recent pre-clinical and clinical data support the use of 153Sm-DOTMP in the pain management of prostate cancer bone metastases, addressing a critical unmet patient need after progression from other radionuclide and radiation therapies. Telix is optimistic about the broader application of the drug in metastatic lung and breast cancer, where patients often face brain and bone metastases, underscoring the potential for enhanced quality-of-life palliative care.

Further adding to the significance of this acquisition, 153Sm-DOTMP has received Orphan Drug and Rare Pediatric Disease Designations from the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. This expands Telix’s portfolio to include a potential treatment for a disease predominantly affecting children and young adults, aligning with Telix’s established focus in musculoskeletal oncology.

Dr Behrenbruch added “Samarium is a highly optimal radionuclide for treating bone metastases, and the combination of ODD and PRDD status with Telix’s demonstrated experience in pharmacy-based cold-kit distribution has strong potential for a rapid pathway to commercialisation of this asset.”

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the ONLY one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The exclusive leadership and influencer podcasts and vodcasts add huge value to our breaking news coverage. The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Federal Health Minister meets with private hospital leaders to tackle sector reforms

Federal Health Minister meets with private hospital leaders to tackle sector reforms

Health Industry Hub | June 20, 2024 |

MedTech & Diagnostics News: In the past five years, 71 private hospital services have closed down as a result of […]

More


News & Trends - Pharmaceuticals

Medicines Australia warns against panic buying or stockpiling of drugs facing supply shortages

Medicines Australia warns against panic buying or stockpiling of drugs facing supply shortages

Health Industry Hub | June 20, 2024 |

Pharma News: Over 400 medicines are currently facing shortages nationwide, according to the Therapeutic Goods Administration (TGA). Among these, 39 […]

More


News & Trends - MedTech & Diagnostics

HCF partners with clinicians to optimise colonoscopy procedures in public hospitals

HCF partners with clinicians to optimise colonoscopy procedures in public hospitals

Health Industry Hub | June 20, 2024 |

MedTech & Diagnostics News: As Australia marks Bowel Cancer Awareness Month this June, the HCF Research Foundation highlights its support […]

More


Digital & Innovation

Australian AI-powered tool promises rapid stroke detection

Australian AI-powered tool promises rapid stroke detection

Health Industry Hub | June 20, 2024 |

Digital & Innovation: An Australian innovation promises to transform stroke care by enabling quicker intervention and improving patient outcomes through […]

More


This content is copyright protected. Please subscribe to gain access.